Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

NCT04498793 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer

Interventions

BIOLOGICAL: Tislelizumab
DRUG: Nab paclitaxel
DRUG: Doxorubicin
DRUG: Epirubicin
DEVICE: Cyclophosphamide

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]
[object Object]